Robert W. Baird Lowers Definitive Healthcare (NASDAQ:DH) Price Target to $6.00

Definitive Healthcare (NASDAQ:DH) had its target price reduced by Robert W. Baird from $8.00 to $6.00 in a research report released on Wednesday morning, Benzinga reports. Robert W. Baird currently has a neutral rating on the stock.

Other research analysts also recently issued reports about the company. Morgan Stanley downgraded Definitive Healthcare from an overweight rating to an equal weight rating and lowered their target price for the company from $11.50 to $9.00 in a research report on Wednesday, May 8th. Stifel Nicolaus lowered their price target on shares of Definitive Healthcare from $11.00 to $9.50 and set a buy rating for the company in a report on Wednesday, May 8th. Deutsche Bank Aktiengesellschaft decreased their price objective on Definitive Healthcare from $10.00 to $7.00 and set a hold rating on the stock in a research report on Thursday, May 9th. William Blair reissued an outperform rating on shares of Definitive Healthcare in a research report on Tuesday, May 14th. Finally, JPMorgan Chase & Co. downgraded Definitive Healthcare from a neutral rating to an underweight rating and lowered their price target for the stock from $7.00 to $5.00 in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of Hold and an average target price of $8.45.

Definitive Healthcare Price Performance

Shares of NASDAQ:DH opened at $3.70 on Wednesday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 2.30 and a current ratio of 2.30. The firm has a market cap of $436.34 million, a price-to-earnings ratio of -2.11, a P/E/G ratio of 4.58 and a beta of 1.30. The firm has a fifty day moving average price of $5.44 and a 200 day moving average price of $7.04. Definitive Healthcare has a fifty-two week low of $3.19 and a fifty-two week high of $11.60.

Definitive Healthcare (NASDAQ:DH) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04). The firm had revenue of $63.48 million for the quarter, compared to analysts’ expectations of $64.00 million. Definitive Healthcare had a negative net margin of 78.16% and a positive return on equity of 0.51%. As a group, sell-side analysts expect that Definitive Healthcare will post 0.09 earnings per share for the current fiscal year.

Institutional Trading of Definitive Healthcare

Large investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC lifted its holdings in Definitive Healthcare by 599.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,786 shares of the company’s stock valued at $58,000 after buying an additional 4,959 shares in the last quarter. Norden Group LLC bought a new stake in shares of Definitive Healthcare during the first quarter valued at approximately $83,000. Berry Wealth Group LP bought a new position in Definitive Healthcare in the first quarter worth approximately $99,000. Reynders McVeigh Capital Management LLC purchased a new position in Definitive Healthcare during the 4th quarter worth $129,000. Finally, Arizona State Retirement System raised its position in Definitive Healthcare by 13.6% during the 4th quarter. Arizona State Retirement System now owns 14,253 shares of the company’s stock valued at $142,000 after purchasing an additional 1,701 shares in the last quarter. 98.67% of the stock is owned by hedge funds and other institutional investors.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.